0000899243-18-018026.txt : 20180625
0000899243-18-018026.hdr.sgml : 20180625
20180625211402
ACCESSION NUMBER: 0000899243-18-018026
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180625
FILED AS OF DATE: 20180625
DATE AS OF CHANGE: 20180625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Onyx Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744260
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38542
FILM NUMBER: 18918140
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
BUSINESS PHONE: 805-447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38542
FILM NUMBER: 18918141
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER NAME:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kezar Life Sciences, Inc.
CENTRAL INDEX KEY: 0001645666
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473366145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-822-5600
MAIL ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-25
1
0001645666
Kezar Life Sciences, Inc.
KZR
0001744260
Onyx Therapeutics, Inc.
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
0
0
1
0
0000318154
AMGEN INC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
0
0
1
0
Common Stock
2018-06-25
4
C
0
1121384
A
1121384
D
Series A Redeemable Convertible Preferred Stock
2018-06-25
4
C
0
1121384
0.00
D
Common Stock
1121384
0
D
As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock.
These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx.
Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.
/s/ Andrea A. Robinson, Assistant Secretary and Associate General Counsel on behalf of Onyx Therapeutics, Inc. and Amgen Inc.
2018-06-25